Contrasting the limited therapeutic effect of SPINK1-targeting agents projected for SPINK1+ individuals in PCa patients, SPINK1 mAb-based therapies against the TME take advantage of circumventing the need to stratify cancer patients according to any molecularly defined attributes. The gene discussed is SPINK1; the disease is posterior cortical atrophy.